Literature DB >> 16603613

Evaluation of multiplex flow cytometric opsonophagocytic assays for determination of functional anticapsular antibodies to Streptococcus pneumoniae.

Joseph E Martinez1, Elizabeth A Clutterbuck, Han Li, Sandra Romero-Steiner, George M Carlone.   

Abstract

The determination of functional antipneumococcal capsular polysaccharide antibodies by sequential testing of pre- and postvaccination serum samples one serotype at a time is sample-intensive and time-consuming and has a relatively low throughput. We tested several opsonophagocytic assay (OPA) formats, including the reference killing method, a monovalent bacterium-based flow method, a trivalent bacterium-based flow method, and a tetravalent bead-based flow method using a panel of sera (4 prevaccination and 16 postvaccination, from healthy adults immunized with the 23-valent pneumococcal polysaccharide vaccine). The trivalent and tetravalent methods allow simultaneous measurements of opsonic antibodies to multiple pneumococcal serotypes. The trivalent bacterial-flow OPA had significant correlation to the reference OPA method and to a previously published flow cytometric OPA (r values ranged from 0.61 to 0.91, P < 0.05) for serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F. The tetravalent OPA had significant correlation to all OPA method formats tested (r values from 0.68 to 0.92, P < 0.05) for all seven serotypes tested. This tetravalent OPA is an alternative to other OPA methods for use during vaccine evaluation and clinical trials. Further, the flow cytometric multiplex OPA format has the potential for expansion beyond the current four serotypes to eight or more serotypes, which would further increase relative sample throughput while reducing reagent and sample volumes used.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16603613      PMCID: PMC1459634          DOI: 10.1128/CVI.13.4.459-466.2006

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  20 in total

1.  Development of a multi-specificity opsonophagocytic killing assay.

Authors:  M H Nahm; D E Briles; X Yu
Journal:  Vaccine       Date:  2000-06-01       Impact factor: 3.641

2.  Opsonophagocytosis of fluorescent polystyrene beads coupled to Neisseria meningitidis serogroup A, C, Y, or W135 polysaccharide correlates with serum bactericidal activity.

Authors:  Joseph Martinez; Tamara Pilishvili; Suzanne Barnard; Joseph Caba; Willie Spear; Sandra Romero-Steiner; George M Carlone
Journal:  Clin Diagn Lab Immunol       Date:  2002-03

Review 3.  Enzyme-linked immunosorbent assay for quantitation of human antibodies to pneumococcal polysaccharides.

Authors:  Catherine M Wernette; Carl E Frasch; Dace Madore; George Carlone; David Goldblatt; Brian Plikaytis; William Benjamin; Sally A Quataert; Steve Hildreth; Daniel J Sikkema; Helena Käyhty; Ingileif Jonsdottir; Moon H Nahm
Journal:  Clin Diagn Lab Immunol       Date:  2003-07

Review 4.  Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants.

Authors:  Luis Jódar; Jay Butler; George Carlone; Ron Dagan; David Goldblatt; Helena Käyhty; Keith Klugman; Brian Plikaytis; George Siber; Robert Kohberger; Ih Chang; Thomas Cherian
Journal:  Vaccine       Date:  2003-07-04       Impact factor: 3.641

5.  Approach to validating an opsonophagocytic assay for Streptococcus pneumoniae.

Authors:  Branda T Hu; Xinhong Yu; Thomas R Jones; Carol Kirch; Sarah Harris; Stephen W Hildreth; Dace V Madore; Sally A Quataert
Journal:  Clin Diagn Lab Immunol       Date:  2005-02

6.  Streptococcus pneumoniae-associated human macrophage apoptosis after bacterial internalization via complement and Fcgamma receptors correlates with intracellular bacterial load.

Authors:  Farzana Ali; Margaret E Lee; Francesco Iannelli; Gianni Pozzi; Tim J Mitchell; Robert C Read; David H Dockrell
Journal:  J Infect Dis       Date:  2003-10-10       Impact factor: 5.226

7.  Efficiency of a pneumococcal opsonophagocytic killing assay improved by multiplexing and by coloring colonies.

Authors:  Kyung Hyo Kim; Jigui Yu; Moon H Nahm
Journal:  Clin Diagn Lab Immunol       Date:  2003-07

8.  Multilaboratory evaluation of a viability assay for measurement of opsonophagocytic antibodies specific to the capsular polysaccharides of Streptococcus pneumoniae.

Authors:  Sandra Romero-Steiner; Carl Frasch; Nelydia Concepcion; David Goldblatt; Helena Käyhty; Merja Väkeväinen; Craig Laferriere; Dominique Wauters; Moon H Nahm; Mark F Schinsky; Brian D Plikaytis; George M Carlone
Journal:  Clin Diagn Lab Immunol       Date:  2003-11

9.  Multiplex opsonophagocytosis assay (MOPA): a useful tool for the monitoring of the 7-valent pneumococcal conjugate vaccine.

Authors:  D Bogaert; M Sluijter; R De Groot; P W M Hermans
Journal:  Vaccine       Date:  2004-09-28       Impact factor: 3.641

Review 10.  Immunity to Streptococcus pneumoniae: Factors affecting production and efficacy.

Authors:  Julio Casal; David Tarragó
Journal:  Curr Opin Infect Dis       Date:  2003-06       Impact factor: 4.915

View more
  9 in total

1.  Pneumococcal capsular polysaccharide vaccine-mediated protection against serotype 3 Streptococcus pneumoniae in immunodeficient mice.

Authors:  Haijun Tian; Avi Groner; Marianne Boes; Liise-anne Pirofski
Journal:  Infect Immun       Date:  2007-01-12       Impact factor: 3.441

Review 2.  Pneumococcal vaccine and opsonic pneumococcal antibody.

Authors:  Joon Young Song; M Allen Moseley; Robert L Burton; Moon H Nahm
Journal:  J Infect Chemother       Date:  2013-05-09       Impact factor: 2.211

3.  Development and validation of a fourfold multiplexed opsonization assay (MOPA4) for pneumococcal antibodies.

Authors:  Robert L Burton; Moon H Nahm
Journal:  Clin Vaccine Immunol       Date:  2006-09

4.  The efficacy of pneumococcal capsular polysaccharide-specific antibodies to serotype 3 Streptococcus pneumoniae requires macrophages.

Authors:  Kevin Fabrizio; Catherine Manix; Haijun Tian; Nico van Rooijen; Liise-anne Pirofski
Journal:  Vaccine       Date:  2010-08-26       Impact factor: 3.641

5.  The effect of age on the response to the pneumococcal polysaccharide vaccine.

Authors:  Hyunju Lee; Moon H Nahm; Kyung-Hyo Kim
Journal:  BMC Infect Dis       Date:  2010-03-10       Impact factor: 3.090

Review 6.  Correlates of Protection for M Protein-Based Vaccines against Group A Streptococcus.

Authors:  Shu Ki Tsoi; Pierre R Smeesters; Hannah R C Frost; Paul Licciardi; Andrew C Steer
Journal:  J Immunol Res       Date:  2015-05-25       Impact factor: 4.818

7.  The impact of B-cell perturbations on pneumococcal conjugate vaccine response in HIV-infected adults.

Authors:  Thomas G Johannesson; Ole S Søgaard; Martin Tolstrup; Mikkel S Petersen; Jens M Bernth-Jensen; Lars Østergaard; Christian Erikstrup
Journal:  PLoS One       Date:  2012-07-30       Impact factor: 3.240

8.  Novel polysaccharide-protein conjugates provide an immunogenic 13-valent pneumococcal conjugate vaccine for S. pneumoniae.

Authors:  Allison E B Turner; Jonas E Gerson; Helen Y So; Daniel J Krasznai; Adrienne J St Hilaire; Donald F Gerson
Journal:  Synth Syst Biotechnol       Date:  2017-01-20

9.  Prime-boost vaccination strategy enhances immunogenicity compared to single pneumococcal conjugate vaccination in patients receiving conventional DMARDs, to some extent in abatacept but not in rituximab-treated patients.

Authors:  Per Nived; Göran Jönsson; Bo Settergren; Jon Einarsson; Tor Olofsson; Charlotte Sværke Jørgensen; Lillemor Skattum; Meliha C Kapetanovic
Journal:  Arthritis Res Ther       Date:  2020-02-22       Impact factor: 5.156

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.